Intraperitoneal anti-PD-L1 increases survival in a novel ovarian cancer model and its in vivo efficacy is influenced by baseline anti-tumor immunity of the host

被引：0
|
作者：
Mony, Jyothi
Zhang, Lixin
Tirodkar, Tejas
Elishaev, Esther
Brozick, Joan
Edwards, Robert P.
Vlad, Anda M.
机构：
[1] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA
[2] Magee Womens Res Inst, Pittsburgh, PA USA
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷
关键词：
D O I：
10.1158/1557-3265.OVCASYMP14-POSTER-THER-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
THER-1434
引用
收藏
页数：2
相关论文
共 50 条
  • [1] In vivo efficacy of intraperitoneal anti-PD-L1 therapy in ovarian cancer
    Grabosch, Shannon
    Mony, Jyothi T.
    Zhang, Lixin
    Ma, Tianzhou
    Tirodkar, Tejas
    Brozick, Joan
    Tseng, George
    Elishaev, Esther
    Edwards, Robert P.
    Huang, Xin
    Vlad, Anda M.
    CANCER RESEARCH, 2015, 75
  • [2] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
    Maohua Li
    Rongqing Zhao
    Jianxin Chen
    Wenzhi Tian
    Chenxi Xia
    Xudong Liu
    Yingzi Li
    Song Li
    Hunter Sun
    Tong Shen
    Wenlin Ren
    Le Sun
    Scientific Reports, 11
  • [3] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
    Li, Maohua
    Zhao, Rongqing
    Chen, Jianxin
    Tian, Wenzhi
    Xia, Chenxi
    Liu, Xudong
    Li, Yingzi
    Li, Song
    Sun, Hunter
    Shen, Tong
    Ren, Wenlin
    Sun, Le
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [4] Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
    Maohua Li
    Rongqing Zhao
    Jianxin Chen
    Wenzhi Tian
    Chenxi Xia
    Xudong Liu
    Yingzi Li
    Song Li
    Hunter Sun
    Tong Shen
    Wenlin Ren
    Le Sun
    Scientific Reports, 12
  • [5] Unleashing anti-tumor immunity through anti-OX40 monotherapy and in combination with anti-PD-L1
    Kim, Jeong M.
    CANCER RESEARCH, 2015, 75
  • [6] Natural and anti-PD-L1 induced tumor immunity in a novel ovarian cancer mouse model for human mucin 1 (MUC1)
    Zhang, Lixin
    Tirodkar, Tejas
    Elishaev, Esther
    Mony, Jyothi
    Brozick, Jone
    Edwards, Robert
    Vlad, Anda
    JOURNAL OF IMMUNOLOGY, 2014, 192
  • [7] Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo (vol 11, 5774, 2021)
    Li, Maohua
    Zhao, Rongqing
    Chen, Jianxin
    Tian, Wenzhi
    Xia, Chenxi
    Liu, Xudong
    Li, Yingzi
    Li, Song
    Sun, Hunter
    Shen, Tong
    Ren, Wenlin
    Sun, Le
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [8] The effect of anemia on immunity in cancer patients and anti-PD-L1 efficacy in tumor-bearing mouse model
    Wang, Z.
    Long, H.
    Zhu, B.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1769 - 1769
  • [9] MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
    Yi, Ruibin
    Hong, Shuo
    Zhang, Yueming
    Lin, Anqi
    Ying, Haoxuan
    Zou, Weidong
    Wang, Qiongyao
    Wei, Ting
    Cheng, Quan
    Zhu, Weiliang
    Luo, Peng
    Zhang, Jian
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [10] A Novel Chimeric Poxvirus Encoding an Anti-PD-L1 Protein Shows Safety and Anti-Tumor Activity in Breast Cancer Model
    Chaurasiya, Shyambabu
    Lu, Jianming
    Kim, Sang-In
    Warner, Susanne G.
    Woo, Yanghee
    Chen, Nanhai G.
    Fong, Yuman
    MOLECULAR THERAPY, 2019, 27 (04) : 192 - 192
12345